echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > ICER evaluates Roctavian and EtranaDez gene therapy for hemophilia A and B

    ICER evaluates Roctavian and EtranaDez gene therapy for hemophilia A and B

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hemophilia is mostly a hereditary disease that prevents the body from clotting and forming a blood clot to stop bleedi.


    The Institute for Clinical and Economic Review (ICER) announced that it will evaluate the clinical efficacy and value of EtranaDez (etranacogene dezaparvovec) in the treatment of hemophili.


    EtranaDez is an AAV5-mediated gene therapy that delivers the Padua variant of the factor IX gene to liver cells, resulting in an active variant of factor .


    The results showed that the annualized bleeding rate (ABR) assessed 18 months after infusion decreased to 51, compared with 19 in the run-in period, meeting the primary noninferiority endpoint as well as secondary endpoin.


     

    Original source:

    Original source:

    https://firstwordphar.


    https://firstwordphar.
    com/story/5565489 https://firstwordphar.
    com/story/5565489Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.